Plasticizers Cross the Placenta: Study Finds ‘Safer’ Alternatives Reaching the Fetus

A new study from Tunisia has delivered one of the most detailed pictures yet of how plastic-softening chemicals move through the bodies of pregnant women and reach the developing fetus. Researchers monitored 198 pregnant women of middle-class background at the maternity ward of a hospital in Monastir and measured plasticizer concentrations in four biological matrices: maternal blood, urine, placental tissue, and amniotic fluid. Using gas chromatography coupled with tandem mass spectrometry (GC–MS/MS), the team detected seven plasticizers spanning both classic phthalate esters and their non-phthalate replacements. The findings, published in Environmental Geochemistry and Health, reveal a clear maternal–fetal exposure continuum and raise uncomfortable questions about whether the chemicals marketed as safer substitutes are truly an improvement.

Phthalate esters are among the most widely produced plasticizer families in the world. They are added to polyvinyl chloride and countless consumer goods—food packaging, cosmetics, personal care products, medical devices, floor coverings, and nail polish—to make rigid plastics flexible and durable. Because phthalates are not chemically bound to the polymer matrix, they leach, migrate, and evaporate into food, dust, water, and air. Decades of toxicological work have classified several of them as endocrine-disrupting chemicals, capable of interfering with hormone signaling, reproductive development, and metabolic regulation. Regulatory agencies in the European Union and the United States have restricted a series of the most concerning compounds, including DEHP, DBP, BBP, and DiBP, particularly in toys and childcare articles, prompting industry to pivot toward alternative plasticizers such as terephthalates and adipates.

That pivot is precisely what makes the new data so striking. The most prevalent plasticizer detected across all four maternal and fetal matrices was DEHT, or di(2-ethylhexyl) terephthalate, a structural isomer of the restricted DEHP that is widely promoted as a safer replacement. DEHT recorded the highest geometric mean concentration in urine at 403.7 micrograms per kilogram, followed by placenta at 318.6 micrograms per kilogram, blood at 304.5 micrograms per kilogram, and amniotic fluid at 275.0 micrograms per kilogram. In other words, a chemical introduced to reduce risk is now the dominant plasticizer burden in pregnant women, and it is not staying in the mother. Its presence in amniotic fluid—the liquid bathing the fetus—demonstrates that substitution has not eliminated fetal exposure, it has changed the chemical profile of that exposure.

Among the classical phthalates, the short-chain compounds told their own story. Diisobutyl phthalate (DiBP) showed the highest concentrations in placental tissue, at 195.8 micrograms per kilogram, and in urine, at 226.0 micrograms per kilogram, indicating both substantial body burden and efficient renal clearance. Dimethyl phthalate (DMP) and diethyl phthalate (DEP), lower-molecular-weight esters commonly found in cosmetics, fragrances, and personal care formulations, were mainly detected in amniotic fluid, at 128.2 and 64.8 micrograms per kilogram respectively. The distribution pattern is chemically meaningful: smaller, more water-soluble molecules tend to partition differently across biological membranes than bulkier, lipophilic ones, and their accumulation in amniotic fluid suggests they can traverse the placental barrier and equilibrate within the fetal compartment.

The placenta is often described as a protective shield, but pharmacologically it behaves more like a semi-permeable membrane governed by physicochemical rules. Molecular size, lipophilicity, ionization state, and protein binding all determine whether a compound crosses by passive diffusion, facilitated transport, or is retained. Plasticizers, being moderately lipophilic and of low molecular weight, are well positioned to cross. The Tunisian team’s measurements confirm this: substantial amounts of both phthalate and non-phthalate plasticizers were found on the fetal side of the barrier. Although the renal system contributes significantly to elimination—reflected in the high urinary concentrations of DEHT and DiBP—excretion is evidently not fast enough to prevent transplacental transfer during pregnancy.

The health implications of prenatal exposure are the subject of a growing and sobering literature. Phthalates have been linked in epidemiological and experimental studies to altered reproductive development, preterm delivery, changes in fetal growth parameters, and disruption of placental function-related genes. Research on the placental methylome and transcriptome suggests that phthalate exposure during the first trimester can reprogram gene regulation at a critical developmental window. Experimental work has also documented oxidative damage and suppression of the Wnt/β-catenin signaling pathway in placental tissue following dibutyl phthalate exposure. For the non-phthalate alternatives, the toxicological record is thinner but increasingly concerning; recent in silico and in vitro studies have flagged diisobutyl adipate, one of the compounds detected in this cohort, for potential lipid metabolism-disrupting effects.

Exposure sources for pregnant women are pervasive and difficult to avoid. Phthalates migrate from PVC food packaging into fatty foods, leach from bottled beverages, and contaminate spices, herbs, and dairy products, as previous surveys of Tunisian and Mediterranean markets by some of the same research groups have documented. Cosmetics and personal care products contribute dermal exposure, with DEP in particular a common ingredient of fragranced formulations. Indoor dust carries plasticizers shed from floorings, wall coverings, and consumer goods, while medical devices can deliver direct doses to vulnerable patients. The Monastir cohort, drawn from middle-class households, underscores that this is not an exposure limited to industrial workers or heavily polluted environments—it is a background exposure affecting the general population of expectant mothers.

The study’s analytical approach deserves attention because measuring parent plasticizers in biological matrices is technically demanding. These compounds are rapidly metabolized in the body into monoester metabolites, which are the usual targets of human biomonitoring in urine. Detecting the parent compounds themselves in placenta, amniotic fluid, blood, and urine, at geometric means ranging from tens to hundreds of micrograms per kilogram, provides a snapshot of circulating chemical burden rather than merely of recent excretion. The multi-matrix design is what allows the exposure continuum to be reconstructed: chemicals present in maternal blood and urine, retained in placental tissue, and dissolved in amniotic fluid trace a pathway from external exposure to the fetal environment.

The authors argue that their findings support further evaluation of both phthalates and their substitutes, and the data give that call force. If DEHT, the flagship replacement, now dominates the exposure profile of pregnant women and penetrates the amniotic cavity, then regulatory success measured by the disappearance of restricted phthalates may mask a regrettable substitution problem, in which one hazardous chemical is swapped for another whose safety profile is unproven in humans. The researchers emphasize the need for improved exposure control, especially for vulnerable populations such as pregnant women and developing fetuses. For now, the study stands as a technical warning: the plastic chemistry of modern life does not stop at the placental barrier, and the burden of proof is shifting to the alternatives that industry hoped would close the chapter on phthalate risk.

Subject of Research: Occurrence and placental transfer of phthalate and non-phthalate plasticizers in maternal and fetal biological matrices

Article Title: Occurrence, distribution and potential sources of phthalate and non-phthalate plasticizers in maternal and fetal-related biological matrices

Article References: Occurrence, distribution and potential sources of phthalate and non-phthalate plasticizers in maternal and fetal-related biological matrices. (n.d.). https://doi.org/10.1007/s10653-026-03540-x

Image Credits: AI Generated

DOI: 10.1007/s10653-026-03540-x

Keywords: phthalates, plasticizers, DEHT, endocrine disruptors, prenatal exposure, placental transfer, amniotic fluid, human biomonitoring, GC-MS/MS, Tunisia, pregnancy, non-phthalate alternatives